ROIV vs. CRNX, BIO, QGEN, ASND, LEGN, PEN, HSIC, RGEN, CHE, and EHC
Should you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Crinetics Pharmaceuticals (CRNX), Bio-Rad Laboratories (BIO), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Penumbra (PEN), Henry Schein (HSIC), Repligen (RGEN), Chemed (CHE), and Encompass Health (EHC). These companies are all part of the "medical" sector.
Roivant Sciences (NASDAQ:ROIV) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Roivant Sciences has a net margin of 3,624.14% compared to Crinetics Pharmaceuticals' net margin of -4,223.27%. Roivant Sciences' return on equity of -33.38% beat Crinetics Pharmaceuticals' return on equity.
Roivant Sciences has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.
Roivant Sciences presently has a consensus price target of $16.90, suggesting a potential upside of 55.33%. Crinetics Pharmaceuticals has a consensus price target of $54.00, suggesting a potential upside of 27.69%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Crinetics Pharmaceuticals.
Crinetics Pharmaceuticals received 93 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.00% of users gave Roivant Sciences an outperform vote while only 66.18% of users gave Crinetics Pharmaceuticals an outperform vote.
64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by company insiders. Comparatively, 7.0% of Crinetics Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Crinetics Pharmaceuticals has lower revenue, but higher earnings than Roivant Sciences. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Roivant Sciences had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 6 mentions for Roivant Sciences and 3 mentions for Crinetics Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 1.40 beat Roivant Sciences' score of 0.44 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.
Summary
Roivant Sciences beats Crinetics Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Roivant Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Roivant Sciences Competitors List
Related Companies and Tools
